Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Case 6: Implementing Current Guidelines and Best Practices for Monitoring and Mitigating Immune-Related Adverse Events
Case 6: Implementing Current Guidelines and Best Practices for Monitoring and Mitigating Immune-Related Adverse Events
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Case 1: How Should I Choose Between Single-Agent IO or IO/Chemotherapy in Patients With PD-L1 = 50% and No Driver Mutations?
Case 1: How Should I Choose Between Single-Agent IO or IO/Chemotherapy in Patients With PD-L1 = 50% and No Driver Mutations?
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?